Yüklüyor......
First-in-child use of the oral selective prostacyclin IP receptor agonist selexipag in pulmonary arterial hypertension
Pulmonary arterial hypertension (PAH) is a complex disease with a poor prognosis. Selexipag is a selective prostacyclin receptor agonist with vasodilatory, anti-proliferative, anti-inflammatory, and pro-angiogenic properties. However, no clinical data on its therapeutic use in children with PAH are...
Kaydedildi:
| Yayımlandı: | Pulm Circ |
|---|---|
| Asıl Yazarlar: | , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
SAGE Publications
2017
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5467934/ https://ncbi.nlm.nih.gov/pubmed/28597771 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2045893217703369 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|